Company news
CLEO Diagnostics Ltd news in 2026
CLEO Diagnostics Ltd's news releases, calls and decks from 2026, newest first.
Quarterly activities and cashflow report
October 30, 2026
Quarterly activities and cashflow report
October 30, 2026
CLEO Screening Test Meets Rigorous Performance Targets
October 20, 2026
CLEO Screening Test Meets Rigorous Performance Targets
October 20, 2026
CLEO Commences Analytical Validation Ahead of FDA Submission
October 12, 2026
Cleo Files Patents for its Ovarian Cancer Screening Test
September 29, 2026
CLEO Commences Ovarian Cancer Screening Test Development
September 23, 2026
Letter to Shareholders
September 16, 2026
Notice of Annual General Meeting/Proxy Form
September 16, 2026
Notice Required Under ASX Listing Rule 3.13.1
September 10, 2026
CLIA Certified Lab selected - Pivotal US Clinical Validation
September 9, 2026
CLEO Receives First Batch of Commercial Test Kits
September 2, 2026
Change of Director's Interest Notice x 4
August 24, 2026
Cleansing Notice
August 24, 2026
Application for quotation of securities - COV
August 24, 2026
Notification of cessation of securities - COV
August 24, 2026
Change in Director's Interest Notice
August 21, 2026
Appendix 4E and 2026 Annual Report
August 20, 2026
Appendix 4G and Corporate Governance Statement
August 20, 2026
Quarterly activities and cashflow report
July 28, 2026
CLEO Enters Analytical Validation Phase
July 12, 2026
CLEO Establishes U.S. Reimbursement Pathway
May 19, 2026
CLEO Commences Kit Manufacturing Ahead of FDA Submission
April 27, 2026
Sample Collection Completion for Pivotal US Clinical Trial
March 30, 2026
CLEO Optimises Biomarker Panel Ahead of FDA Submission
March 22, 2026
Appendix 4D and Half Yearly Accounts
February 25, 2026
CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
February 17, 2026
Quarterly activities and cashflow report
January 28, 2026